-
Article
Open AccessPathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia
Autoantibodies that bind the N-methyl-D-aspartate receptor (NMDAR) may underlie glutamate receptor hypofunction and related cognitive impairment found in schizophrenia. Exposure to neurotropic pathogens can foste...
-
Article
Open AccessSystem-based proteomic and metabonomic analysis of the Df(16)A+/− mouse identifies potential miR-185 targets and molecular pathway alterations
Deletions on chromosome 22q11.2 are a strong genetic risk factor for development of schizophrenia and cognitive dysfunction. We employed shotgun liquid chromatography–mass spectrometry (LC-MS) proteomic and me...
-
Article
Open AccessSerum proteomic profiles of depressive subtypes
Depression is a highly heterogeneous disorder. Accumulating evidence suggests biological and genetic differences between subtypes of depression that are homogeneous in symptom presentation. We aimed to evaluat...
-
Article
Open AccessCytokine production capacity in depression and anxiety
Recent studies have suggested that immune function may be dysregulated in persons with depressive and anxiety disorders. Few studies examined the expression of cytokines in response to ex vivo stimulation of bloo...
-
Article
Open AccessProteomics investigation identifies prominent changes in synapse-related proteins in a fragile X mouse model
-
Article
Open AccessDevelopment of a blood-based molecular biomarker test for identification of schizophrenia before disease onset
Recent research efforts have progressively shifted towards preventative psychiatry and prognostic identification of individuals before disease onset. We describe the development of a serum biomarker test for t...
-
Article
Open AccessSerum proteomic profiling of major depressive disorder
Much has still to be learned about the molecular mechanisms of depression. This study aims to gain insight into contributing mechanisms by identifying serum proteins related to major depressive disorder (MDD) ...
-
Article
Open AccessEvidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia
Molecular abnormalities in metabolic, hormonal and immune pathways are present in peripheral body fluids of a significant subgroup of schizophrenia patients. The authors have tested whether such disturbances a...
-
Article
Open AccessDiabetic db/db mice exhibit central nervous system and peripheral molecular alterations as seen in neurological disorders
The db/db mouse is a widely used preclinical model in diabetes research. Recent studies have shown that these mice also display aspects of psychosis and depression-like behaviors as seen in some psychiatric disor...
-
Article
Identification of a biological signature for schizophrenia in serum
Biomarkers are now used in many areas of medicine but are still lacking for psychiatric conditions such as schizophrenia (SCZ). We have used a multiplex molecular profiling approach to measure serum concentrat...
-
Article
Open AccessIdentification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients
Major depressive disorder (MDD) is a leading cause of disability worldwide and results tragically in the loss of almost one million lives in Western societies every year. This is due to poor understanding of t...
-
Article
Open AccessIdentification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients
The current inability of psychiatric medicine to objectively select the most appropriate treatment or to predict imminent relapse are major factors contributing to the severity and clinical burden of schizophr...
-
Article
Sex-specific serum biomarker patterns in adults with Asperger's syndrome
Autism spectrum conditions have been hypothesized to be an exaggeration of normal male low-empathizing and high-systemizing behaviors. We tested this hypothesis at the molecular level by performing comprehensi...
-
Article
Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients
Extensive research has been conducted on post-mortem brain tissue in schizophrenia (SCZ), particularly the dorsolateral prefrontal cortex (DLPFC). However, to what extent the reported changes are due to the di...
-
Article
Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients
Little is known about the biological mechanisms underpinning the pathology of schizophrenia. We have analysed the proteome of stimulated and unstimulated peripheral blood mononuclear cells (PBMCs) from schizop...
-
Article
Global proteomic profiling reveals altered proteomic signature in schizophrenia serum
Schizophrenia is one of the most severe psychiatric disorders affecting 1% of the world population. There is yet no empirical method to validate the diagnosis of the disease. The identification of an underlyin...
-
Article
Differential effects on T-cell function following exposure to serum from schizophrenia smokers
Cigarette smoking is more prevalent in subjects with schizophrenia compared to those with other psychiatric disorders or the general population and could therefore affect molecular pathways that impact the pat...
-
Article
Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients
-
Article
Elevated S100B levels in schizophrenia are associated with insulin resistance
-
Article
Erratum: Differential effects on T-cell function following exposure to serum from schizophrenia smokers
Correction to: Molecular Psychiatry advance online publication 11 November 2008; doi: 10.1038/mp.2008.120 Following the online publication of the above article, the authors noted the following errors in Figure...
